Form 4: Puma Biotechnology Director Michael Miller Granted 27,000 Restricted Stock Units

Puma Biotechnology, Inc. Director Michael Patrick Miller was granted 27,000 shares of common stock in the form of Restricted Stock Units, increasing his direct beneficial ownership to 74,000 shares.

Summary

• Michael Patrick Miller, a Director of Puma Biotechnology, Inc. (PBYI), acquired 27,000 shares of common stock.
• The acquisition occurred on June 11, 2025, and was in the form of Restricted Stock Units (RSUs).
• These RSUs were granted at a price of $0 per share.
• Following this transaction, Mr. Miller's direct beneficial ownership of Puma Biotechnology common stock increased to 74,000 shares.
• The RSUs are subject to a vesting schedule, vesting in full on the earlier of the one-year anniversary of the grant date or the date of the annual shareholder meeting following the grant date, contingent on Mr. Miller's continued service.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive event as it aligns the director's interests with shareholders and is a standard form of compensation, indicating continued commitment. It does not, however, represent a direct cash investment by the director.

Positives

• The grant of 27,000 Restricted Stock Units to Director Michael Patrick Miller aligns his interests with those of shareholders, as the value of these units is tied to the company's stock performance.
• The increase in Mr. Miller's beneficial ownership to 74,000 shares demonstrates continued commitment from a key board member.

Negatives

• No specific negative information is disclosed in this Form 4 filing.

Risks

• The vesting of the Restricted Stock Units is contingent on Michael Patrick Miller's continued service with Puma Biotechnology, Inc., meaning the shares could be forfeited if his service terminates before vesting.

Future Outlook

The Restricted Stock Units granted to Director Michael Patrick Miller are set to vest in full on the earlier of the one-year anniversary of the grant date (June 11, 2026) or the date of the annual shareholder meeting following the grant date, provided his continued service to the company.

Industry Context

This transaction is a standard equity compensation practice for directors in publicly traded biotechnology companies, aiming to align executive and board member incentives with long-term shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a common form of non-cash compensation in the biotechnology and broader corporate sectors, aligning director interests with shareholder value.
• The vesting schedule, tied to continued service and a one-year anniversary or next annual meeting, is typical for such grants, ensuring retention and performance incentives.
• The grant price of $0 for RSUs is standard, as RSUs represent a promise to deliver shares upon vesting, not an immediate purchase.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• The Restricted Stock Units will vest on the earlier of June 11, 2026 (one-year anniversary of grant) or the date of the annual shareholder meeting following the grant date, subject to continued service.

Key Dates

Keywords

Puma Biotechnology, PBYI, Michael Patrick Miller, Director, Restricted Stock Units, RSU, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership